Elevation Oncology, Inc. (ELEV) has a consensus analyst rating of Hold, based on 12 analysts covering the stock. Of those, 3 recommend buying, 8 recommend holding, and 1 recommend selling.
The analyst consensus price target for ELEV is $9.00, representing a +2,365.8% upside from the current price of $0.365. Price targets range from a low of $8.00 to a high of $10.00.
